The abstract is read at the publisher; the summary is JClub's.
Oral YAQ007 lowered ammonia by day 5 in cirrhosis patients with prior overt hepatic encephalopathy, with significant reductions at 4 g twice daily and 4 g three times daily.
- Why it matters: Ammonia is central to hepatic encephalopathy, yet no approved therapies directly target ammonia, leaving a treatment gap for short-term biochemical control.
- What they did: In a randomized, open-label, multicenter phase 2a inpatient study, 48 cirrhosis patients received 5 days of oral YAQ007 (2 g three times daily; 4 g twice daily; 4 g three times daily) or rifaximin 550 mg twice daily, with ammonia measured through day 5.
- The result: Ammonia decreased at day 5 in group C (p=0.009) and group B (p=0.002), urinary phenylacetylglutamine excretion rose across all YAQ007 doses (p<0.001), and safety was generally mild with treatment-emergent adverse events in 55.6% vs 41.7%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.